ENCell, a bio-pharmaceutical contract development and manufacturing organization (CDMO), announced on the 4th that it has signed a CDMO contract worth 800 million won with the domestic corporation Celebrain.

The contract period lasts until March 3, 2026. The main details of the contract were not disclosed due to a confidentiality agreement between the two companies.

ENCell is the number one corporation in the domestic cell gene CDMO sector based on sales and market share. It offers a one-stop service through its Good Manufacturing Practice (GMP) facilities capable of producing both cells and viruses simultaneously.

Celebrain is developing gene stem cell therapies that incorporate functional genes into stem cells targeting brain diseases such as brain tumors and strokes.

Jang Jong-wook, CEO of ENCell, noted, "We will strive to produce gene-loaded stem cell therapies from the master cell bank (MCB) with ENCell's core CDMO technologies, aiming to apply them in advanced regenerative clinical research and treatments."

Seo Hae-young, CEO of Celebrain, said, "Through this contract, we will work hard to prove the innovative therapeutic potential by entering into late-stage clinical trials both domestically and internationally with the therapies produced."